Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States

Click to increase image sizeClick to decrease image size

Disclosure statement

T. Bhutani is an investigator for AbbVie, Janssen, Merck, Eli Lilly, and Strata Skin Sciences.

S. R. Feldman is a consultant for Amgen, Baxter, Caremark, Gerson Lehrman Group, Guidepoint Global, Hanall Pharmaceutical Co Ltd, Kikaku, Lilly, Merck & Co Inc., Merz Pharmaceuticals, Mylan, Novartis Pharmaceuticals, Pfizer Inc, Qurient, Suncare Research, and Xenoport. He is on an advisory board for Pfizer Inc. S. R. Feldman is the founder of and holds stock in Causa Research, and holds stock and is majority owner in Medical Quality Enhancement Corporation. He receives royalties from UpToDate and Xlibris.

V. Y. Shi is a stock shareholder of Dermveda, has served as a paid advisor for Menlo Therapeutics and the National Eczema Association, received educational grant and honorarium from Sanofi and Pfizer, and lectureship honorarium from Novartis. The other authors have no other conflicts of interest to declare.

Data availability

The data that support the findings of this study are available in the Medicaid Pharmacy Pricing database at https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/index.html.

Additional information

Funding

S. R. Feldman has received grants from Galderma, Janssen, Abbott Labs, Amgen, Stiefel, GlaxoSmithKline, Celgene, and Anacor.